Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 307
Filter
1.
J Pediatr Surg ; 59(6): 1044-1049, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38195357

ABSTRACT

BACKGROUND: Despite the initiation of minimally invasive laparoscopic techniques, the majority of patients who undergo anorectal malformation repair still experience functional bowel issues in childhood, including constipation and fecal incontinence. In this study, we evaluate the functional outcomes of a procedure in which magnetic resonance imaging guidance is used during initial laparoscopic repair to better locate the epicenter of the sphincter muscle complex and pelvic floor with the goal of more accurate placement of the neoanus and improved functional outcomes. METHODS: A retrospective chart review evaluated demographic, operative, and outcome details for patients who underwent this procedure. A telephone survey was employed to determine levels of social continence using the validated Baylor Continence Scale and to determine what type of bowel management is used. RESULTS: Twenty-six patients were included. Median age at operation was 7 months, and median age at follow-up was 4 years old, with a range of 1-9. Bowel management regimen results revealed that 19 % (n = 5) use no bowel management regimen, 58 % (n = 15) use laxatives only, and 23 % (n = 6) use enemas. Enema use was not associated with different spine or sacral anomalies (p = 0.77). Fifteen patients (58 %) answered the Baylor Continence Scale questions and had a median score of 14. No difference was found in scores when accounting for lesion level (p = 0.43), quality of needle placement (p = 0.46), or quality of sphincter muscles (p = 0.75). CONCLUSIONS: Using MRI guidance in the repair of anorectal malformations shows promise in both the qualitative and quantitative functional outcomes of this complex patient population. LEVEL OF EVIDENCE: Level III.


Subject(s)
Anorectal Malformations , Fecal Incontinence , Magnetic Resonance Imaging , Humans , Retrospective Studies , Male , Female , Magnetic Resonance Imaging/methods , Anorectal Malformations/surgery , Fecal Incontinence/etiology , Infant , Child, Preschool , Treatment Outcome , Laparoscopy/methods , Follow-Up Studies , Constipation/etiology , Anal Canal/abnormalities , Anal Canal/surgery , Child , Surgery, Computer-Assisted/methods , Rectum/surgery , Rectum/abnormalities , Postoperative Complications/etiology , Enema/methods , Anus, Imperforate/surgery , Anus, Imperforate/diagnostic imaging , Laxatives/therapeutic use , Laxatives/administration & dosage
2.
Food Funct ; 12(17): 7709-7717, 2021 Sep 07.
Article in English | MEDLINE | ID: mdl-34286775

ABSTRACT

Dietary fiber is the basic therapeutic method to relieve the symptoms of chronic constipation. The aim of this study was to compare the laxative effect of konjac glucomannan (KGM) and konjac oligosaccharides (KOS) on constipated rats. KGM and KOS were administered to loperamide-induced constipated rats at dosages of 100 mg per kg bw and 400 mg per kg bw for 15 days. Feces were collected to evaluate the defecation function. X-ray imaging and an electrophysiological system were used to determine gastrointestinal (GI) motility. Immunohistochemistry and western blotting were used to measure the protein levels. Magnetic resonance imaging (MRI) was performed to assess flatulence. Our results demonstrated that low-dose KOS (L-KOS) exerted the best laxative effect. Compared to the normal control (NC) group, the fecal number in the L-KOS group increased by 39.4%, and the fecal weight significantly increased by 31.9% which was higher than those in the low-dose KGM (L-KGM) and high-dose KGM (H-KGM) groups. The fecal moisture content and transit scores were significantly increased only in the L-KOS group. Meanwhile, less GI gas was produced by KOS. Additionally, further investigations suggested that KOS could upregulate the protein expression of stem cell factors (SCF)/c-kit, and significantly promoted the secretion of mucus. In conclusion, compared to KGM, KOS had a conspicuous laxative effect especially at a low dosage. The potential laxative mechanisms of KOS probably are regulating the SCF/c-kit signalling pathway and increasing mucus secretion. These findings indicated that as a kind of functional oligosaccharide, KOS is more conducive to alleviating constipation compared to polysaccharides.


Subject(s)
Amorphophallus/chemistry , Constipation/drug therapy , Laxatives/administration & dosage , Mannans/administration & dosage , Oligosaccharides/administration & dosage , Plant Extracts/administration & dosage , Animals , Constipation/chemically induced , Constipation/metabolism , Constipation/physiopathology , Defecation , Feces/chemistry , Humans , Loperamide/adverse effects , Male , Rats , Rats, Sprague-Dawley , Stem Cell Factor/genetics , Stem Cell Factor/metabolism
3.
J Surg Oncol ; 124(7): 1106-1114, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34310702

ABSTRACT

BACKGROUND AND OBJECTIVES: Recent studies suggest that bacteria influence the pathogenesis of primary colorectal cancer (CRC), yet their role in recurrence after resection is largely unknown. We have discovered that collagenase-producing bacteria promote cancer recurrence in mice, and that antibiotic bowel decontamination decreases colonization of these same organisms in humans. We hypothesized that preoperative combined mechanical and oral antibiotic bowel preparation would improve disease-free survival (DFS) in patients undergoing surgery for CRC. METHODS: We reviewed a cancer registry of patients treated for CRC at a tertiary center. Patients who received bowel preparation were compared to those that did not via a 1:1-propensity score matched for follow-up, age, sex, BMI, stage, location, chemoradiation, infection, anastomotic leak, and blood transfusion. RESULTS: One thousand two hundred and seventy-nine patients met inclusion criteria. Following propensity score matching, 264 patients receiving bowel prep were matched to 264 patients who did not. Kaplan-Meier estimates showed that patients who received bowel prep had a significantly improved 5-year DFS compared to those that did not (76.3% vs. 64.2%; p < .01). Cox regression demonstrated that bowel prep was associated with improved DFS (HR, 0.57; 95% CI, 0.37-0.89; p < .01). CONCLUSION: Combined mechanical and oral antibiotic bowel preparation is independently associated with improved recurrence-free survival in patients undergoing surgery for CRC.


Subject(s)
Antibiotic Prophylaxis , Colorectal Neoplasms/mortality , Colorectal Neoplasms/surgery , Disease-Free Survival , Laxatives/administration & dosage , Adenocarcinoma/surgery , Adolescent , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Humans , Male , Matched-Pair Analysis , Middle Aged , Preoperative Care , Registries , Retrospective Studies , Young Adult
4.
Medicine (Baltimore) ; 100(20): e25760, 2021 May 21.
Article in English | MEDLINE | ID: mdl-34011036

ABSTRACT

BACKGROUND: Modified Runchang-Tang (MRCT), a Chinese herbal medicine, is widely used to treat functional constipation (FC), which is a common digestive system disease. However, its efficacy has not been evaluated systematically and objectively. Thus, a meta-analysis was conducted to assess the efficacy and safety of MRCT for treating functional constipation. METHODS: We searched for relevant publications from Embase, Medline, The Cochrane Library, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, Chinese Scientific Journals Database, and Wanfang Data for relevant literature. The timeframe of retrieval was set from the founding date of each database to July 15, 2020. RESULT: A total of 26 randomized controlled trials with 2103 individuals were included in this meta-analysis. All trials were conducted in mainland China and were written in Chinese. The results showed that MRCT monotherapy provided better symptom relief in FC patients compared to prokinetic agent monotherapy (odds ratio, [OR] = 4.06), osmotic laxatives (OR = 4.39) and stimulant laxatives (OR = 2.99). Additionally, there were no obvious adverse effects in MRCT group compared with control group. CONCLUSION: MRCT treatment is an efficient and safe treatment for FC. However, considering the limitations of this study, further well-designed randomized controlled trials are required to validate this conclusion.


Subject(s)
Constipation/drug therapy , Drugs, Chinese Herbal/administration & dosage , Laxatives/administration & dosage , Prescription Drugs/administration & dosage , China , Constipation/diagnosis , Flax/chemistry , Humans , Laxatives/adverse effects , Prescription Drugs/adverse effects , Randomized Controlled Trials as Topic , Rheum/chemistry , Treatment Outcome
5.
Gastroenterol Hepatol ; 44(10): 696-703, 2021 Dec.
Article in English, Spanish | MEDLINE | ID: mdl-33872625

ABSTRACT

INTRODUCTION: Small bowel capsule endoscopy (SBCE) is a non-invasive diagnostic technique whose use in inflammatory bowel disease (IBD) has spread. A panenteric capsule, PillCam Crohn's (PCC), has recently been developed. We lack information on the availability and use of the CEID and PCC in our environment. METHODS: We conducted an electronic and anonymous survey among the members of the Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) [Spanish Working Group on Crohn's Disease and Ulcerative Colitis] and the Asociación Española de Gastroenterología (AEG) [Spanish Association of Gastroenterology], consisting of 37 multiple-choice questions. RESULTS: One hundred and fifty members participated, the majority dedicated to IBD (69.3%). 72.8% worked at centres with an IBD unit. 79% had SBCE available at their hospital, 14% referred patients to another centre; 22% had a PCC available, 9% referred patients to another centre. 79.3% of respondents with available SBCE used it in a small percentage of patients with IBD and 15.6% in the majority. The most frequent scenarios were suspicion of Crohn's disease (76.3%), assessment of inflammatory activity (54.7%) and assessment of the extent of the disease (54.7%). More than half (59.7%) preferentially used the Patency capsule to assess intestinal patency. Almost all respondents (99.3%) considered that training resources should be implemented in this technique. CONCLUSIONS: SBCE is widely available in Spanish hospitals for the management of IBD, although its use is still limited. There is an opportunity to increase training in this technique, and consequently its use.


Subject(s)
Capsule Endoscopy/statistics & numerical data , Colitis, Ulcerative/diagnostic imaging , Crohn Disease/diagnostic imaging , Gastroenterology/statistics & numerical data , Health Care Surveys/statistics & numerical data , Capsule Endoscopy/education , Female , Gastroenterology/education , Humans , Laxatives/administration & dosage , Male , Societies, Medical , Spain
6.
Nutrients ; 13(4)2021 Mar 25.
Article in English | MEDLINE | ID: mdl-33805862

ABSTRACT

BACKGROUND: Like other combat sports, sambo has competition rules that divide athletes into categories based on gender, age and weight. Athletes in combat sports often resort to rapid weight loss (RWL) methods to be more competitive in lower weight categories and gain an advantage against lighter, smaller and weaker competitors. The aim of this study was to examine the methodology implemented by two different sambo age categories, junior and senior athletes, in order to attain RWL. METHODS: The sample consisted of 103 male sambo elite athletes (seniors/juniors: age 28.5 ± 4.3/18.9 ± 0.8; height (m): 1.7 ± 0.1/1.8 ± 0.1; weight (kg): 76.3 ± 17.8/74.4 ± 16.3; BMI (kg/m2): 25.0 ± 3.8/23.7 ± 3.9) who completed a survey on RWL. RESULTS: Athletes reported losing a mean of 5 kg starting approximately 12 days before a competition. The most common methodology reported by senior and junior sambo athletes was gradually increasing dieting, followed by sauna and plastic suit training. Less common methods adopted were laxatives, diuretics, the use of diet pills and vomiting. There were significant group differences for sauna and diet pill ingestion. Coaches and parents are influential people in the lives of athletes concerning the weight loss strategy to be adopted. CONCLUSIONS: This study's results unequivocally confirm the prevalent practice of RWL in both senior and junior sambo athletes. Although athletes prevalently chose "less harmful" methods, there is a need to inform parents and coaches of the risks and benefits of RWL.


Subject(s)
Athletes/statistics & numerical data , Martial Arts/statistics & numerical data , Weight Loss , Adolescent , Adult , Age Factors , Diuretics/administration & dosage , Humans , Laxatives/administration & dosage , Male , Steam Bath/statistics & numerical data , Surveys and Questionnaires , Time , Vomiting
7.
PLoS One ; 16(2): e0246363, 2021.
Article in English | MEDLINE | ID: mdl-33626068

ABSTRACT

To investigate the role of tannin-enriched extracts of Ecklonia cava (TEE) on the regulation of oxidative balance and laxative activity in chronic constipation, we investigated alterations after exposure to TEE, on constipation phenotypes, muscarinic cholinergic regulation, and oxidative stress responses in the transverse colons of SD rats with loperamide (Lop)-induced constipation. This extract contains high levels of total condensed tannin content (326.5 mg/g), and exhibited high inhibitory activity against 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals. TEE treatment induced significant improvements in reactive oxygen species (ROS) production, superoxide dismutase (SOD) expression and nuclear factor erythroid 2-related factor 2 (Nrf2) phosphorylation in primary smooth muscles of rat intestine cells (pRISMCs) and transverse colon of constipation model. Also, Lop+TEE treated groups showed alleviated outcomes for the following: most stool parameters, gastrointestinal transit, and intestine length were remarkably recovered; a similar recovery pattern was observed in the histopathological structure, mucin secretion, water channel expression and gastrointestinal hormones secretion in the transverse colon; expressions of muscarinic acetylcholine receptors M2/M3 (mAChR M2/M3) and their mediators on muscarinic cholinergic regulation were significantly recovered. Taken together, these results provide the first evidence that TEE stimulates oxidative stress modulation and muscarinic cholinergic regulation when exerting its laxative effects in chronic constipation models.


Subject(s)
Antioxidants , Constipation/drug therapy , Gastrointestinal Transit/drug effects , Laxatives , Plant Extracts , Tannins , Animals , Antioxidants/administration & dosage , Antioxidants/pharmacology , Constipation/chemically induced , Laxatives/administration & dosage , Laxatives/pharmacology , Loperamide , Male , Phaeophyceae/chemistry , Plant Extracts/administration & dosage , Plant Extracts/chemistry , Plant Extracts/pharmacology , Rats , Rats, Sprague-Dawley , Tannins/administration & dosage , Tannins/pharmacology
8.
J Sci Med Sport ; 24(6): 531-535, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33423947

ABSTRACT

OBJECTIVES: Female athletes experience eating disorders (EDs) at clinical, and subclinical, levels; most studies have determined point-prevalence rates through cross-sectional methodologies. To date, few studies have examined the long-term stability of EDs in female athletes; none extend into retirement. DESIGN: A longitudinal investigation of ED classification (i.e., Clinical ED, Subclinical ED, Healthy) and weight control behaviors (e.g., vomiting, laxative use) from when athletes actively competed (T1) into their retirement (T2). METHODS: Participants included U.S. female athletes (N=193) who were collegiate competitors (T1) and eventually were retired from their collegiate sports six years later (T2). RESULTS: At T2, athletes were classified as Healthy (69.9%), Subclinical ED (26.9%), and Clinical ED (3.1%). Overall percentage of Subclinical EDs increased from 18.7% (T1) to 26.9% (T2); 52.8% of T1 Subclinical ED athletes continued to meet criteria for either Subclinical or Clinical ED at T2. Of the 13 Clinical ED athletes at T1, six (46.2%) continued to meet criteria for either a subclinical or clinical ED at T2. Though exercising (2+ hours/day; n=8, 4.1%) and dieting/fasting (4+ times/year; n=14, 7.3%) were the most frequently used weight control behaviors at T2, rates were substantially lower than at T1. CONCLUSIONS: Retirement does not result in immediate remittance of eating concerns among female athletes; many continue or develop Subclinical and Clinical ED symptoms. Thus, addressing healthy body image and nutrition when athletes are competing is imperative to assist prevention and intervention efforts that may alleviate ED symptoms as athletes transition from sport.


Subject(s)
Athletes , Feeding and Eating Disorders/diagnosis , Adult , Age Factors , Athletes/classification , Body Image/psychology , Feeding and Eating Disorders/epidemiology , Feeding and Eating Disorders/prevention & control , Female , Gymnastics/psychology , Gymnastics/statistics & numerical data , Humans , Laxatives/administration & dosage , Longitudinal Studies , Prevalence , Retirement/psychology , Students , Swimming/psychology , Swimming/statistics & numerical data , Time Factors , United States/epidemiology , Universities/statistics & numerical data , Vomiting
9.
Sci Rep ; 11(1): 2482, 2021 01 28.
Article in English | MEDLINE | ID: mdl-33510267

ABSTRACT

Adolescence is a stage in life characterized by important social, cognitive, and physical changes. Adolescents are vulnerable to various psychosocial disorders, including eating disorders. We aimed to investigate the association between unhealthy habits, sociodemographic characteristics, and the practice of self-induced vomiting or laxative misuse in a representative sample of Brazilian adolescent girls and boys. Data from 102,072 students who participated in the National Adolescent School-based Health Survey were analyzed using the dependent variable: presence or absence of self-induced vomiting and/or laxative misuse; independent variables: consumption of unhealthy and high-calorie food items, age during first sexual intercourse, and the use of tobacco, alcohol, and/or illicit drugs. Associations between exposure and outcome were estimated using Poisson's regression models stratified by sex, and including region, school, age group, and mother's educational history as adjustment variables. Eating ultra-processed foods and age during first sexual intercourse were associated with self-induced vomiting and laxative misuse only for girls; all other variables (consuming unhealthy foods and using legal or illicit substances) were associated with these behaviors for both sexes after applying adjustment variables. Early interventions focusing on changing unhealthy behaviors may prevent development of eating disorders in adolescents. Our findings demonstrate a strong association of many unhealthy habits with laxative misuse and self-induced vomiting practices in Brazilian adolescents.


Subject(s)
Adolescent Behavior , Feeding Behavior , Feeding and Eating Disorders , Habits , Laxatives/adverse effects , Students , Vomiting , Adolescent , Brazil/epidemiology , Child , Feeding and Eating Disorders/chemically induced , Feeding and Eating Disorders/epidemiology , Female , Humans , Laxatives/administration & dosage , Male , Sex Factors
10.
Clin Transl Gastroenterol ; 11(11): e00255, 2020 11.
Article in English | MEDLINE | ID: mdl-33259160

ABSTRACT

OBJECTIVES: Chronic constipation (CC) is a recurrent functional bowel disorder worldwide. The purpose of this study is to examine its pooled placebo response rate and compare placebo response level in randomized controlled trials (RCTs) with different endpoint assessments. METHODS: PubMed, Cochrane Library, and Embase were electronically searched for therapeutic RCTs of CC with placebo control. Data extraction and assessment of risk of bias were performed independently by 2 reviewers. All the statistical calculation and analysis were performed using R 3.6.0. Our protocol has registered in PROSPERO with registration number: CRD42019121287. RESULTS: There were 46 studies included with 5,992 constipated patients allocated to the placebo arm in total. The pooled placebo response rate was 28.75% (95% confidence interval: 23.83%-33.67%) with significant heterogeneity among trials ((Equation is included in full-text article.)= 93.6%). Treatment efficacy assessed using subjective improvement had a significantly higher placebo response rate than that assessed with improvement in complete (spontaneous) bowel movements or composite improvement (41.40% vs 18.31% or 20.35%, P < 0.001). According to the results of meta-regression, active treatment and endpoint assessment were most likely to lead to the huge heterogeneity among studies. DISCUSSION: Patients with CC have significant response level to placebo. Based on findings in this study, we do not recommend subjective improvement as endpoint while designing therapeutic RCTs for chronic constipated patients.


Subject(s)
Constipation/therapy , Dietary Supplements , Laxatives/administration & dosage , Outcome Assessment, Health Care/methods , Serotonin 5-HT4 Receptor Agonists/administration & dosage , Chronic Disease/therapy , Cross-Over Studies , Humans , Outcome Assessment, Health Care/statistics & numerical data , Placebo Effect , Placebos/administration & dosage , Randomized Controlled Trials as Topic
11.
Arq. bras. med. vet. zootec. (Online) ; 72(5): 1625-1630, Sept.-Oct. 2020. tab, graf
Article in English | LILACS, VETINDEX | ID: biblio-1131536

ABSTRACT

Magnesium sulphate (MS) and dioctyl sodium sulphosuccinate (DSS) are laxative drugs frequently used for the treatment of impactions. The aim of this study was to compare the effects of MS and DSS in fecal hydration, output and systemic hydration in healthy horses. Five healthy horses received 3 treatments with a 21-day interval. Treatment 1 was performed with administration of 4 liters of warm water; treatment 2: administration of 4 liters of warm water associated with 1g/kg of MS; and treatment 3: administration of 4 liters of warm water associated with 20mg/kg DSS. General and specific physical examination of the digestive system were performed, alongside with packed cell volume and total plasma protein measurement, abdominal ultrasonography and quantification of the amount and hydration of feces, before and 6, 12, 24, 36 and 48 hours after the treatments. No adverse effects were observed. The administration of laxatives promoted greater fecal output and hydration without resulting in systemic dehydration, yet no differences were observed between treatments. The absence of adverse effects of DSS demonstrates the safety of its use as a laxative drug at a dose of 20mg/kg. Studies comparing the effects of the laxative drugs in horses with large colon impaction are needed.(AU)


O sulfato de magnésio (SM) e o dioctil-sulfossuccinato de sódio (DSS) são drogas laxativas frequentemente utilizadas no tratamento da compactação. O objetivo deste estudo foi comparar os efeitos do SM e do DSS na hidratação e eliminação fecal, e na hidratação sistêmica de cavalos saudáveis. Cinco cavalos receberam três tratamentos, com intervalo de 21 dias. O tratamento 1 consistiu na administração de quatro litros de água morna; o tratamento 2: administração de quatro litros de água morna associada a 1g/kg de SM; e o tratamento 3: administração de quatro litros de água morna associada a 20mg/kg de DSS. Foram realizados exames físicos gerais e específicos do trato digestivo, hematócrito e proteína plasmática total, ultrassonografia abdominal e mensuração da quantidade e hidratação das fezes antes e após seis, 12, 24, 36 e 48 horas dos tratamentos. Não foram observados efeitos adversos. A administração de ambos os laxantes promoveu maior produção fecal e hidratação, sem resultar em desidratação sistêmica, entretanto não houve diferença entre os tratamentos. A ausência de efeitos adversos do DSS demonstra a segurança de seu uso como medicamento laxante na dose de 20mg/kg. São necessários estudos que comparem o efeito dos laxantes em equinos portadores de compactação de cólon.(AU)


Subject(s)
Animals , Colon/pathology , Dioctyl Sulfosuccinic Acid/therapeutic use , Laxatives/administration & dosage , Fecal Impaction/therapy , Horses , Magnesium Sulfate/therapeutic use , Fecal Impaction/veterinary , Fluid Therapy/methods
12.
United European Gastroenterol J ; 8(10): 1217-1227, 2020 12.
Article in English | MEDLINE | ID: mdl-32838693

ABSTRACT

BACKGROUND: Bowel preparation for colonoscopy is often poorly tolerated due to poor palatability and adverse effects. This can negatively impact on the patient experience and on the quality of bowel preparation. This systematic review and meta-analysis was carried out to assess whether adjuncts to bowel preparation affected palatability, tolerability and quality of bowel preparation (bowel cleanliness). METHODS: A systematic search strategy was conducted on PubMed, MEDLINE, EMBASE and the Cochrane Database of Systematic Reviews to identify studies evaluating adjunct use for colonoscopic bowel preparation. Studies comparing different regimens and volumes were excluded. Specific outcomes studied included palatability (taste), willingness to repeat bowel preparation, gastrointestinal adverse events and the quality of bowel preparation. Data across studies were pooled using a random-effects model and heterogeneity assessed using I2-statistics. RESULTS: Of 467 studies screened, six were included for analysis (all single-blind randomised trials; n = 1187 patients). Adjuncts comprised citrus reticulata peel, orange juice, menthol candy drops, simethicone, Coke Zero and sugar-free chewing gum. Overall, adjunct use was associated with improved palatability (mean difference 0.62, 95% confidence interval 0.29-0.96, p < 0.001) on a scale of 0-5, acceptability of taste (odds ratio 2.75, 95% confidence interval: 1.52-4.95, p < 0.001) and willingness to repeat bowel preparation (odds ratio 2.92, 95% confidence interval: 1.97-4.35, p < 0.001). Patients in the adjunct group reported lower rates of bloating (odds ratio 0.48, 95% confidence interval: 0.29-0.77, p = 0.003) and vomiting (odds ratio 0.47, 95% confidence interval 0.27-0.81, p = 0.007), but no difference in nausea (p = 0.10) or abdominal pain (p = 0.62). Adjunct use resulted in superior bowel cleanliness (odds ratio 2.52, 95% confidence interval: 1.31-4.85, p = 0.006). Heterogeneity varied across outcomes, ranging from 0% (vomiting) to 81% (palatability), without evidence of publication bias. The overall quality of evidence was rated moderate. CONCLUSION: In this meta-analysis, the use of adjuncts was associated with better palatability, less vomiting and bloating, willingness to repeat bowel preparation and superior quality of bowel preparation. The addition of adjuncts to bowel preparation may improve outcomes of colonoscopy and the overall patient experience.


Subject(s)
Colonoscopy/methods , Laxatives/administration & dosage , Pharmaceutic Aids/administration & dosage , Preoperative Care/methods , Colonoscopy/statistics & numerical data , Humans , Laxatives/adverse effects , Laxatives/chemistry , Patient Outcome Assessment , Patient Satisfaction , Pharmaceutic Aids/chemistry , Randomized Controlled Trials as Topic , Taste , Treatment Outcome
13.
Lancet Gastroenterol Hepatol ; 5(11): 996-1007, 2020 11.
Article in English | MEDLINE | ID: mdl-32805205

ABSTRACT

BACKGROUND: The laxative drug lubiprostone improves intestinal permeability in healthy volunteers. We aimed to assess efficacy and safety of lubiprostone in patients with non-alcoholic fatty liver disease (NAFLD) with constipation via attenuation of intestinal permeability. METHODS: This randomised, double-blind, placebo-controlled, phase 2a study in Yokohama City University Hospital, Japan, recruited patients (aged 20-85 years) with NAFLD and constipation, alanine aminotransferase (ALT) at least 40 U/L, liver stiffness (≤6·7 kPa), and hepatic fat fraction at least 5·2% when assessed by MRI-proton density fat fraction. Eligible patients were randomly assigned (11:10:9) by a computer-based system and stratified by age and sex to receive 24 µg lubiprostone, 12 µg lubiprostone, or placebo, orally, once per day for 12 weeks. The primary endpoint was the absolute changes in ALT at 12 weeks. Efficacy analysis was done by intention to treat. Safety was assessed in all treated patients. This trial was registered with University Hospital Medical Information Network Clinical Trials Registry (UMIN000026635). FINDINGS: Between March 24, 2017, and April 3, 2018, we screened 288 patients, of whom 150 (52%) were randomly assigned to treatment: 55 patients were assigned to receive 24 µg lubiprostone, 50 to receive 12 µg lubiprostone, and 45 to receive placebo. A greater decrease in the absolute ALT levels from baseline to 12 weeks was seen in the 24 µg lubiprostone group (mean -13 U/L [SD 19]) than in the placebo group (1 U/L [24]; mean difference -15 U/L [95% CI -23 to -6], p=0·0007) and in the 12 µg lubiprostone group (-12 U/L [21]) than in the placebo group (mean difference -13 U/L [-22 to -5], p=0·0023). 18 (33%) of 55 patients in the 24 µg group had at least one adverse event, as did three (6%) of 47 patients in the 12 µg group and three (7%) of 43 in the placebo group. The most common adverse event was diarrhoea (17 [31%] of patients in the 24 µg group, three [6%] in the 12 µg group, none in the placebo group). No life-threatening events or treatment-related deaths occurred. INTERPRETATION: Lubiprostone was well tolerated and reduced the levels of liver enzymes in patients with NAFLD and constipation. Further studies are necessary to better define the efficacy and tolerability of lubiprostone in patients with NAFLD without constipation. FUNDING: Mylan EPD G.K.


Subject(s)
Alanine Transaminase/blood , Diarrhea , Liver , Lubiprostone , Non-alcoholic Fatty Liver Disease , Constipation/drug therapy , Constipation/etiology , Diarrhea/chemically induced , Diarrhea/diagnosis , Dose-Response Relationship, Drug , Double-Blind Method , Drug Monitoring/methods , Elasticity Imaging Techniques/methods , Female , Humans , Laxatives/administration & dosage , Laxatives/adverse effects , Liver/diagnostic imaging , Liver/metabolism , Liver Function Tests , Lubiprostone/administration & dosage , Lubiprostone/adverse effects , Male , Middle Aged , Non-alcoholic Fatty Liver Disease/blood , Non-alcoholic Fatty Liver Disease/complications , Non-alcoholic Fatty Liver Disease/physiopathology , Treatment Outcome
14.
J Clin Pharm Ther ; 45(5): 927-936, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32672366

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: The imbalance in serum potassium caused by laxatives can negatively affect the cardiovascular system, leading to life-threatening consequences. Our objective was to evaluate the reported evidence of adverse events related to the cardiac system due to laxative-induced hypokalaemia from case reports. METHODS: A systematic electronic literature search of PubMed, Embase, the Cochrane Library and Science Direct was conducted for the period 1995-2019. In these databases, search terms describing hypokalaemia and cardiotoxicity were combined with the term laxative use. RESULTS AND DISCUSSION: Over the 23 years, 27 incidents were identified in 12 countries. There were 19 female and eight male patients, with ages ranging from 1 month to 93 years. The frequency of reported cases according to severity was the following: severe hypokalaemia 48%, moderate hypokalaemia 44.4% and mild hypokalaemia 7.4%. In 70% of patients, the effect of laxative on the heart was typical hypokalaemic electrographic changes, 7.4% showed abnormal changes in cardiac rhythm, whereas in 18.5%, the cardiotoxicity observed was a very serious kind. Two patients died due to severe cardiac effects. WHAT IS NEW AND CONCLUSION: The laxatives-along with the involvement of some other contributing factors-caused mild-to-severe hypokalaemic cardiotoxicity. These factors were non-adherence of the patient to the recommended dosage, laxative abuse, drug-drug and drug-disease interactions, non-potassium electrolyte imbalances and the use of herbal laxatives. We recommend that laxatives and aggravating factors should be taken into account in the assessment of patients with suspected hypokalaemic cardiotoxicity.


Subject(s)
Cardiotoxicity/etiology , Hypokalemia/chemically induced , Laxatives/adverse effects , Cardiotoxicity/physiopathology , Dose-Response Relationship, Drug , Drug Interactions , Humans , Hypokalemia/complications , Hypokalemia/physiopathology , Laxatives/administration & dosage , Medication Adherence , Potassium/blood , Severity of Illness Index
15.
Nutrients ; 12(7)2020 Jul 10.
Article in English | MEDLINE | ID: mdl-32664341

ABSTRACT

Functional constipation (FC) is a chronic constipation for which no physiological, anatomical or iatrogenic origin can be evidenced. This condition has a high impact on a patient's quality of life and healthcare costs. Since FC is frequently associated with low physical activity and a diet low in fiber and/or water, first-line recommendations focus on sufficient activity, and sufficient fiber and water intake. In case of inefficacy of these measures, numerous drug treatments are available, either over the counter or on prescription. Magnesium sulfate has a long history in the treatment of FC, and magnesium sulfate-rich mineral waters have been used for centuries for their laxative properties. The laxative effect of magnesium and sulfate has since been widely demonstrated. Nevertheless, it appears that no clinical studies aiming at demonstrating their efficacy in FC had been conducted before the 21st century. In this paper, we reviewed the clinical data reporting the efficacy of magnesium sulfate-rich natural mineral waters. In view of their reported efficacy and safety, magnesium sulfate-rich natural mineral waters may represent a natural treatment for FC.


Subject(s)
Constipation/therapy , Laxatives/administration & dosage , Magnesium Sulfate/administration & dosage , Mineral Waters/administration & dosage , Defecation , Dietary Fiber/administration & dosage , Female , Humans , Magnesium Oxide/administration & dosage , Male , Probiotics/administration & dosage , Quality of Life
16.
United European Gastroenterol J ; 8(8): 923-932, 2020 10.
Article in English | MEDLINE | ID: mdl-32594884

ABSTRACT

BACKGROUND: Few head-to-head comparisons of the different classes of laxatives have been conducted. OBJECTIVE: The objective of this work is to compare the efficacy of lactulose plus paraffin vs polyethylene glycol in the treatment of functional constipation (non-inferiority study). METHODS: This randomised, parallel-group, multicentre phase 4 study recruited patients with functional constipation diagnosed according to Rome III criteria. Patients received lactulose plus paraffin or polyethylene glycol for 28 days. The primary end point was the change from baseline in the Patient Assessment of Constipation-Symptoms (PAC-SYM) score. RESULTS: A total of 363 patients were randomised to lactulose plus paraffin (n = 179) or polyethylene glycol (n = 184). On day 28, the mean PAC-SYM score decreased significantly vs baseline with both treatments (p < 0.001). The lower boundary of the 95% CI exceeded the pre-specified limit of -0.25, therefore establishing non-inferiority of lactulose plus paraffin vs polyethylene glycol. At least one adverse event occurred in 20 patients (11.2%) in the lactulose plus paraffin group and in 26 patients (14.2%) in the polyethylene glycol group, most of which were of mild or moderate severity and unrelated to study drugs. CONCLUSION: Lactulose plus paraffin may be used interchangeably with polyethylene glycol for the pharmacological treatment of functional constipation.Trial registration: EudraCT number 2015-003021-34.


Subject(s)
Constipation/drug therapy , Lactulose/administration & dosage , Laxatives/administration & dosage , Paraffin/administration & dosage , Polyethylene Glycols/administration & dosage , Administration, Oral , Adult , Aged , Constipation/diagnosis , Drug Combinations , Female , Humans , Lactulose/adverse effects , Laxatives/adverse effects , Male , Middle Aged , Paraffin/adverse effects , Polyethylene Glycols/adverse effects , Quality of Life , Severity of Illness Index , Treatment Outcome
18.
PLoS One ; 15(4): e0231888, 2020.
Article in English | MEDLINE | ID: mdl-32343708

ABSTRACT

BACKGROUND AND AIMS: Inadequate bowel preparation (BP) is an unfavorable factor that influence the success of colonoscopy. Although standard education (SE) given to patients are proved useful to avoid inadequate BP. Studies concerning the effects of reinforced education (RE) on the quality of BP were inconsistent. The aim of this updated meta-analysis of randomized controlled trial was to compare the quality of BP between patients receiving RE in addition to SE and those receiving SE alone. METHODS: MEDLINE, EMBASE, Web of Science and the Cochrane Library were systemically searched to identify the relevant studies published through April 2019. The primary outcome was the rate of adequate BP. Subgroup analyses were conducted. Secondary outcomes included BP score, adenoma detection rate (ADR), polyp detection rate (PDR), insertion time, withdrawal time, adverse events, >80% purgative intake and diet compliance. Dichotomous variables were reported as odds ratio (OR) with 95% confidence interval (CI). Continuous data were reported as mean difference (MD) with 95%CI. Pooled estimates of OR or MD were calculated using a random-effects model. Statistical heterogeneity was accessed by calculating the I2 value. A P value less than 0.05 was considered significant. RESULTS: A total of 18 randomized controlled trails (N = 6536) were included in this meta-analysis. Patients who received RE had a better BP quality than those only receiving SE (OR 2.59, 95%CI: 2.09-3.19; P<0.001). A higher ADR (OR 1.35; 95%CI: 1.06-1.72; P = 0.020) and PDR (OR 1.24, 95%CI: 1.02-1.50; P = 0.030), shorter insertion (MD -0.76; 95%CI: -1.48-(-0.04); P = 0.040) and withdrawal time (MD -0.83; 95%CI: -1.83-(-0.28); P = 0.003), less nausea/vomiting (OR 0.78; 95%CI: 0.64-0.97; P = 0.020) and abdominal distension (OR 0.72; 95%CI: 0.68-0.92; P = 0.020) were achieved in the RE group. More patients had >80% purgative intake (OR 2.17; 95%CI, 1.09-4.32; P = 0.030) and were compliant with diet restriction (OR 2.38; 95%CI: 1.79-3.17; P<0.001) in the RE group. CONCLUSION: RE significantly improved BP quality, increased ADR and PDR, decreased insertion and withdrawal time and adverse events.


Subject(s)
Colonoscopy , Patient Education as Topic , Adenoma/pathology , Humans , Laxatives/administration & dosage , Laxatives/adverse effects , Nausea/etiology , Odds Ratio , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/adverse effects , Polyps/pathology , Randomized Controlled Trials as Topic
19.
Pediatr Int ; 62(7): 816-819, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32181978

ABSTRACT

BACKGROUND: This study aimed to evaluate the usefulness, from a therapeutic perspective, of classifying the subtypes of functional childhood constipation using a colon transit time (CTT) test. METHODS: A total of 190 children were enrolled in this study, which was based on data collected from a defecation diary, a CTT test, and medical records. RESULTS: Polyethylene glycol (PEG) 4000 was prescribed in 51.1% (N = 47/92) of normal transit type constipation cases (NT) and 91.8% (N = 90/98) of abnormal transit type constipation cases (P < 0.001). In terms of the subtype of CTT test, PEG 4000 was prescribed in 51.1% (N = 47/92) of NT cases, 96.2% (N = 25/26) of outlet obstruction type cases (OT), and 90.3% (N = 65/72) of slow transit type cases (ST) (P < 0.001). Polyethylene glycol 4000 was administered in 97.2% (N = 35/36) of the fecal incontinence group and 66.2% (N = 102/154) of the non-fecal incontinence group (P < 0.001). In the non-fecal incontinence group, PEG 4000 was prescribed in 47.3% (N = 40/84) of NT cases, 94.4% (N = 17/18) of OT cases, and 86.5% (N = 45/52) of ST cases (P < 0.001). In the fecal incontinence group, PEG 4000 was prescribed in 87.5% (N = 7/8) of NT cases, 100% (N = 8/8) of OT cases, and 100% (N = 20/20) of ST cases (P = 0.165). CONCLUSIONS: Subtype classification of functional constipation based on the CTT test provides important information for the initial choice of drugs in children.


Subject(s)
Constipation/classification , Constipation/drug therapy , Gastrointestinal Agents/administration & dosage , Lactulose/administration & dosage , Polyethylene Glycols/administration & dosage , Adolescent , Child , Child, Preschool , Colon/metabolism , Defecation/drug effects , Fecal Incontinence/drug therapy , Female , Gastrointestinal Transit/drug effects , Humans , Laxatives/administration & dosage , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...